CHARIOT trial (cohort A2): A phase I dose-escalation study combining the ATR inhibitor berzosertib with cisplatin and capecitabine
El Badri, S. Lord, S. Harman, R. McIntosh, D. Mukherjee, S. Ooms, A. Parkes, M. Radhakrishna, Ganesh Shaw, P. H. Hawkins, M. A.
El Badri, S.
Lord, S.
Harman, R.
McIntosh, D.
Mukherjee, S.
Ooms, A.
Parkes, M.
Radhakrishna, Ganesh
Shaw, P. H.
Hawkins, M. A.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
El Badri S, Lord S, Harman R, McIntosh D, Mukherjee S, Ooms A, et al. CHARIOT trial (cohort A2): A phase I dose-escalation study combining the ATR inhibitor berzosertib with cisplatin and capecitabine. Annals of Oncology. 2022 Sep;33(7):S761-S. PubMed PMID: WOS:000866211600477.